linagliptindpp4inhibitor

由 AL Mayer 著作 · 2021 · 被引用 5 次 — DPP-4 inhibition with linagliptin ameliorates renal injury in a rat model of anti-GBM, indicating that linagliptin not only is a secure therapy ...

由 AR Aroor 著作 · 2017 · 被引用 68 次 — Conclusions. We have demonstrated that linagliptin, a DPP-4 inhibitor, improves DD in WD-fed female mice, a clinically relevant model of obesity ...

由 AR Aroor 著作 · 2018 · 被引用 35 次 — In this regard, linagliptin is a unique DPP-4 inhibitor with both CV and renal safety profiles. Moreover, it exerts beneficial CV effects beyond ...

2016年7月21日 — Linagliptin is a DPP-4 inhibitor with a high affinity for DPP-4 in various tissues (15–17). In rodents, linagliptin more effectively reduces DPP ...

由 E Kornelius 著作 · 2015 · 被引用 113 次 — Linagliptin is an inhibitor of dipeptidylpeptidase-4 (DPP-4), which improves impaired insulin secretion and insulin downstream signaling in the in peripheral ...

由 PP Toth 著作 · 2011 · 被引用 17 次 — Linagliptin is a recently approved DPP-4 inhibitor with unique pharmacological properties, including very high affinity for the DPP-4 enzyme, postdose DPP-4 ...

2015年8月28日 — Medicines in the DPP-4 inhibitor class include sitagliptin, saxagliptin, linagliptin, and alogliptin. They are available as single ...

由 K Saini 著作 · 2023 · 被引用 5 次 — Sitagliptin, alogliptin and linagliptin possess high selectivity for DPP-4 due to strong binding with S2-extensive site which is absent in related peptidases ...

由 G Luippold 著作 · 2018 · 被引用 9 次 — Linagliptin binds much longer and therefore has the potential to inhibit renal DPP-4 more sustainable. The doses for sitagliptin used in this study were 3 times ...

由 T Yamaguchi 著作 · 2019 · 被引用 18 次 — Full Paper. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.